Brian Leyland-Jones, MBBS, PhD

home / authors / brian-leyland-jones-mbbs-phd

Articles

Dr. Leyland-Jones on Breast Cancer Risk Assessment Tools

Dr. Leyland-Jones on Breast Cancer Risk Assessment Tools

Brian Leyland-Jones, MBBS, PhD
March 3rd 2014

Brian Leyland-Jones, MBBS, PhD, director, Edith Sanford Breast Cancer Research, discusses the development of breast cancer risk assessment tools.

Read More

Dr. Leyland-Jones Discusses the Phase III HERA Trial

Dr. Leyland-Jones Discusses the Phase III HERA Trial

Brian Leyland-Jones, MBBS, PhD
December 7th 2012

Brian Leyland-Jones, MBBS, PhD, discusses results from the phase III HERA trial that compared 2 years of adjuvant trastuzumab to the standard 1 year in HER2-postive early-stage breast cancer.

Read More

Dr. Leyland-Jones Discusses Genome Sequencing

Dr. Leyland-Jones Discusses Genome Sequencing

Brian Leyland-Jones, MBBS, PhD
February 20th 2012

Dr. Brian Leyland-Jones from Winship Cancer Institute Discusses Genome Sequencing

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data